OT antagonist 1 | Oxytocin Receptor Antagonist | AmBeed-信号通路专用抑制剂

首页 / 抑制剂/激动剂 / / / OT antagonist 1

OT antagonist 1 {[allProObj[0].p_purity_real_show]}

货号：A499733

OT antagonist 1 (Compound 4) is a potent, selective Oxytocin antagonist with a Ki of 50 nM.

OT antagonist 1 化学结构
CAS号：479080-38-1

OT antagonist 1 3D分子结构
CAS号：479080-38-1

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

OT antagonist 1 纯度/质量文件产品仅供科研

货号：A499733 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • JACS Au, 2024. Ambeed. [ A148168 ]; • JMC, 2024. Ambeed. [ A187643 ]; • JMC, 2024. Ambeed. [ A341145 , A633512 , A607865 , A167774 ]; • Biomacromolecules, 2024. Ambeed. [ A110759 ]; • Biomacromolecules, 2024. Ambeed. [ A203543 ]; 更多 >

OX Receptor 亚型比较

产品名称	OX1 receptor ↓ ↑	OX2 receptor ↓ ↑	纯度
SB-408124	++ OX1 (membrane), Ki: 27 nM OX1 (whole cell), Ki: 57 nM		{[allProObj[0].p_purity_real_show]}
SB-334867 free base	✔		{[allProObj[0].p_purity_real_show]}
Almorexant HCl	+++ OX1 receptor, IC50: 6.6 nM	++++ OX2 receptor, IC50: 3.4 nM	{[allProObj[0].p_purity_real_show]}
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

OT antagonist 1 生物活性

描述	OT antagonist 1 (Compound 4) is a potent, selective Oxytocin antagonist with a Ki of 50 nM.

OT antagonist 1 临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT01839253	Orthognathic Surgery	Not Applicable	Completed	-	Korea, Republic of ... 展开 >> Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine Seoul, Korea, Republic of, 120-752 收起 <<
NCT01778049	Diabetes Mellitus, Type 2	Phase 3	Completed	-	-
NCT00857012	-		Completed	-	-

OT antagonist 1 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

2.56mL

0.51mL

0.26mL

12.81mL

2.56mL

1.28mL

25.61mL

5.12mL

2.56mL

OT antagonist 1 技术信息

CAS号	479080-38-1
分子式	C₂₂H₂₂N₄O₃
分子量	390.435

别名
运输	蓝冰

存储条件

粉末

液体 -20°C:3-6个月-80°C:12个月

溶解度

动物实验配方

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT01839253	Orthognathic Surgery	Not Applicable	Completed	-	Korea, Republic of ... 展开 >> Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine Seoul, Korea, Republic of, 120-752 收起 <<
NCT01778049	Diabetes Mellitus, Type 2	Phase 3	Completed	-	-
NCT00857012	-		Completed	-	-
NCT00666458	Type 2 Diabetes	Phase 3	Completed	-	-
NCT01778049	-		Completed	-	-
NCT02188550	Ovarian Cancer ... 展开 >> Endometrial Cancer 收起 <<	Phase 2	Unknown	-	United States, Maryland ... 展开 >> Sinai Hospital of Baltimore, Inc. Recruiting Baltimore, Maryland, United States, 21215 Contact: Judy Bosley, BSN, RN 410-601-6120 jbosley@lifebridgehealth.org Contact: Melissa Loomis 410-601-6120 mloomis@lifebridgehealth.org Principal Investigator: Kenneth Miller, M.D. 收起 <<
NCT00666458	-		Completed	-	-
NCT03481257	-		Completed	-	Korea, Republic of ... 展开 >> Seoul National University Bundang Hospital Seongnam, Gyeonggi-do, Korea, Republic of, 463707 收起 <<
NCT01638988	Polycystic Ovary Syndrome ... 展开 >> Insulin Resistance 收起 <<	Phase 3	Withdrawn(Previous studies hav... 展开 >>e been done regarding same condition) 收起 <<	December 2015	Canada, Quebec ... 展开 >> Clinique Ovo Montréal, Quebec, Canada, H4P 2S4 收起 <<
NCT02389933	-		-	-	-
NCT00776243	-		Completed	-	Korea, Republic of ... 展开 >> Division of Endocrinology and Metabolism, St.Vincent's Hospital Suwon, Kyonggi-do, Korea, Republic of, 442-723 Division of Endocrinology and Metabolism, Kangnam St.Mary's Hospital Seoul, Korea, Republic of, 137-701 收起 <<
NCT00775242	Menopause	Phase 2 Phase 3	Completed	-	Mexico ... 展开 >> Centro A.F. de Estudios Tecnologicos, S.A. Mexico, DF, Mexico, 03100 收起 <<
NCT02226120	Chronic Heart Failure With Red... 展开 >>uced Ejection Fraction 收起 <<	Phase 3	Completed	-	-
NCT02260492	Asthma	Phase 1	Completed	-	-
NCT01263353	Gastroenteropancreatic Neuroen... 展开 >>docrine Tumor of the Pulmonary ot Gastroenteropancreatic System 收起 <<	Phase 1	Completed	-	Germany ... 展开 >> Novartis Investigative Site Bad Berka, Germany, 99438 Novartis Investigative Site Berlin, Germany, 13353 Novartis Investigative Site Marburg, Germany, 35039 Novartis Investigative Site Muenster, Germany, 48149 收起 <<
NCT02465515	Diabetes Mellitus	Phase 4	Completed	-	-
NCT00295347	Major Depression	Not Applicable	Completed	-	Germany ... 展开 >> University Hospital Hamburg-Eppendorf Hamburg, Germany, 20246 收起 <<
NCT00753168	Glaucoma, Open-Angle ... 展开 >> Ocular Hypertension 收起 <<	Phase 1 Phase 2	Completed	-	United States, California ... 展开 >> Artesia, California, United States United States, Georgia Roswell, Georgia, United States United States, North Carolina Charlotte, North Carolina, United States High Point, North Carolina, United States United States, South Carolina Mount Pleasant, South Carolina, United States 收起 <<
NCT02260492	-		Completed	-	-
NCT01836263	-		Unknown	June 2017	France ... 展开 >> Université Paris Descartes, Hôpital Cochin, Service de Rhumatologie A & INSERM 1016 Recruiting Paris, France, 75014 Principal Investigator: Yannick Allanore, Prof. Germany Justus-Liebig-University Gießen, Kerckhoff Clinic, Departement of Rheumatology and Clinical Immunology Recruiting Bad Nauheim, Germany, 61231 Principal Investigator: Ulf Müller-Ladner, Prof. Sub-Investigator: Ingo H. T, Dr. Sub-Investigator: Marc Frerix, Dr. Charité Universitätsmedizin Berlin, Charité Centrum 12 für Innere Medizin und Dermatologie, Medizinische Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie Recruiting Berlin, Germany, 10117 Principal Investigator: Gabriela Riemekasten, Prof. Centre for Pediatric Rheumatology, Klinikum Eilbek Recruiting Hamburg, Germany, 22081 Principal Investigator: Ivan Foeldvari, Dr. Hungary Pecsi Tudomanyegyetem - University of Pecs Recruiting Pecs, Hungary, H-7622 Principal Investigator: Laszlo Czirjak, Prof. Italy University of Florence, Denothe Centre, Division of Rheumatology AOUC, Department of Biomedicine Recruiting Firenze, Italy, 50139 Principal Investigator: Marco Matucci-Cerinic, Prof. Policlinico, Via Pansini Recruiting Napoli-Italia, Italy, 5-80131 Principal Investigator: Gabriele Valentini, Prof. Switzerland Felix-Platter Spital, University of Basel Recruiting Basel, Switzerland, CH 4012 Principal Investigator: Ulrich Walker, Prof. University of Zurich, Department of Rheumatology Recruiting Zurich, Switzerland, 8006 Principal Investigator: Oliver Distler, Prof. United Kingdom The Universitiy of Leeds, Division of Rheumatic and Musculoskeletal Disease, St James's University Hospital Recruiting Leeds, United Kingdom, LS9 7TF Principal Investigator: Francesco Del Galdo, Dr. Royal Free Hospital, University College London Recruiting London, United Kingdom, NW3 2QG Principal Investigator: Christopher Denton, Prof. 收起 <<
NCT03062150	Major Depression	Not Applicable	Recruiting	June 30, 2019	Germany ... 展开 >> Charité Universitätsmedizin Berlin Recruiting Berlin, Germany, 12203 Contact: Christian Otte, Prof. Dr. +49-30-450-517532 Christian.Otte@charite.de 收起 <<

OT antagonist 1 {[allProObj[0].p_purity_real_show]}

OT antagonist 1 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

OT antagonist 1 质控信息

OT antagonist 1 生物活性

OT antagonist 1 临床研究

OT antagonist 1 实验方案

OT antagonist 1 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

OT antagonist 1 {[allProObj[0].p_purity_real_show]}

OT antagonist 1 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

OT antagonist 1 质控信息

OT antagonist 1 生物活性

OT antagonist 1 临床研究

OT antagonist 1 实验方案

OT antagonist 1 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

OT antagonist 1 纯度/质量文件产品仅供科研